(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.51%.
Skye Bioscience's earnings in 2026 is -$57,330,856.On average, 10 Wall Street analysts forecast SKYE's earnings for 2026 to be -$34,634,138, with the lowest SKYE earnings forecast at -$49,594,820, and the highest SKYE earnings forecast at -$21,771,536. On average, 10 Wall Street analysts forecast SKYE's earnings for 2027 to be -$41,223,586, with the lowest SKYE earnings forecast at -$62,682,343, and the highest SKYE earnings forecast at -$21,033,518.
In 2028, SKYE is forecast to generate -$48,751,371 in earnings, with the lowest earnings forecast at -$73,703,414 and the highest earnings forecast at -$22,878,563.